



**Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: **Milton Packer, M.D., M.P.H.**

Committee: **Cardiovascular and Renal Drugs Advisory Committee**

Meeting Date: **July 15, 2021**

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda item described below, I may be considered for participation in the advisory committee meeting:

On July 15, 2021, the committee will discuss new drug application (NDA) 213805, for the hypoxia inducible factor prolyl hydroxylase inhibitor, roxadustat tablets, submitted by FibroGen, Inc., for the treatment of anemia due to chronic kidney disease in adult patients not on dialysis and on dialysis.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
Stocks/investments	Stock holdings in (b) (6) and (b) (6) (competing/affected firm)	(b) (6) : \$0 - \$25,000. Aggregate value: \$25,000 - \$50,000.
II. Other Imputed Interests		
None		

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/S/_____
Signature

_____/06/09/2021_____
Date